Trial Profile
A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine With Olanzapine in Subjects Who Completed Protocol A7501013 [EXTENSION OF 700027130]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Asenapine (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Organon; Pfizer; Schering-Plough
- 28 Mar 2013 New trial record